This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The 5 Dumbest Things on Wall Street This Week: Oct. 18

Stocks in this article: CNDO BBRY JPM SWK C

5. Coronado's Collapse

You know the old Wall Street adage, right? Bulls make money, bears make money and biotechs selling pig parasite eggs get slaughtered.

OK, OK. Maybe that's not the exact phrasing, but it certainly comes pretty close to describing what happened to Coronado BioSciences' (CNDO) stock this week.

Shares of Coronado tumbled 67% to $1.91 Monday after the company announced that its experimental Crohn's Disease treatment failed an important Phase II study. Coronado's drug, which is referred to as CNDO-21, contains the live eggs of a parasite found in the excrement of pigs (also known as Trichuris suis ova, or TSO). When swallowed, the eggs hatch and grow into tiny whipworms which were intended to stimulate a human's immune system and fight off inflammatory auto-immune diseases like Crohn's.

Yes, it's absolutely disgusting to even think about let alone ingest. Nevertheless, you know what they also say: Any pig parasite egg in a storm.

That is, if only Coronado's drug provided shelter from it, which, unfortunately, it doesn't, despite the company's best attempt to spin the sorry results in its favor.

"These results support the potential of TSO to regulate the immune system in patients with Crohn's disease, particularly those with higher level of disease severity," said Coronado CEO Dr. Harlan Weisman. "We look forward to further analyzing the data from TRUST-I, along with the anticipated data from Dr. Falk Pharma's TRUST-II study in Crohn's disease, to identify the most appropriate development path for TSO."

Mixed, mangled and entirely un-kosher metaphors aside, Crohn's symptoms of patients treated with CNDO-021 failed to respond any better than patients treated with a placebo. And as TheStreet's biotech ax Adam Feuerstein alertly points out, blaming negative study results on a higher-than-expected placebo response is typically the "lame excuse" offered when a drug simply doesn't work.

Look. Weisman understands better than anybody the unenviable position he was put in. He's no dummy. However, he still had to offer his disappointed investors some kind of hope even though his so-called "path for TSO" now looks like a dead end.

What else could he do while standing up there with pig parasite egg on his face?

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs